TY - JOUR
T1 - Ribonucleotide reductase inhibitors and future drug design
AU - Shao, J.
AU - Zhou, B.
AU - Chu, Bernard
AU - Yen, Y.
PY - 2006
Y1 - 2006
N2 - Ribonucleotide reductase (RR) is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for DNA replication and repair. The key role of RR in DNA synthesis and cell growth control has made it an important target for anticancer therapy. Increased RR activity has been associated with malignant transformation and tumor cell growth. Efforts for new RR inhibitors have been made in basic and translational research. In recent years, several RR inhibitors, including Triapine, Gemcitabine, and GTI-2040, have entered clinical trial or application. Furthermore, the discovery of p53R2, a p53-inducible form of the small subunit of RR, raises the interest to develop subunit-specific RR inhibitors for cancer treatment. This review compiles recent studies on (1) the structure, function, and regulation of two forms of RR; (2) the role in tumorigenesis of RR and the effect of RR inhibition in cancer treatment; (3) the classification, mechanisms of action, antitumor activity, and clinical trial and application of new RR inhibitors that have been used in clinical cancer chemotherapy or are being evaluated in clinical trials; (4) novel approaches for future RR inhibitor discovery.
AB - Ribonucleotide reductase (RR) is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for DNA replication and repair. The key role of RR in DNA synthesis and cell growth control has made it an important target for anticancer therapy. Increased RR activity has been associated with malignant transformation and tumor cell growth. Efforts for new RR inhibitors have been made in basic and translational research. In recent years, several RR inhibitors, including Triapine, Gemcitabine, and GTI-2040, have entered clinical trial or application. Furthermore, the discovery of p53R2, a p53-inducible form of the small subunit of RR, raises the interest to develop subunit-specific RR inhibitors for cancer treatment. This review compiles recent studies on (1) the structure, function, and regulation of two forms of RR; (2) the role in tumorigenesis of RR and the effect of RR inhibition in cancer treatment; (3) the classification, mechanisms of action, antitumor activity, and clinical trial and application of new RR inhibitors that have been used in clinical cancer chemotherapy or are being evaluated in clinical trials; (4) novel approaches for future RR inhibitor discovery.
KW - Classification
KW - Clinical trial and application
KW - Drug discovery
KW - Inhibitors
KW - Mechanism of action
KW - Ribonucleotide reductase
KW - Structure and function
UR - http://www.scopus.com/inward/record.url?scp=33745823841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745823841&partnerID=8YFLogxK
U2 - 10.2174/156800906777723949
DO - 10.2174/156800906777723949
M3 - Review article
C2 - 16918309
AN - SCOPUS:33745823841
SN - 1568-0096
VL - 6
SP - 409
EP - 431
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
IS - 5
ER -